Translating molecular advances in fragile x syndrome into therapy: A review

Journal of Clinical Psychiatry

Volumn 75, Issue 4, 2014, Pages

  Hagerman, Randi J ^a   Des Portes, Vincent ^b,c   Gasparini, Fabrizio ^d   Jacquemont, Sébastien ^e   Gomez Mancilla, Baltazar ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HCL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d NOVARTIS PHARMA AG   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ACAMPROSATE; ARBACLOFEN; DONEPEZIL; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; GANAXOLONE; LITHIUM; MAVOGLURANT; MELATONIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; MINOCYCLINE; NPL 2009; OXYTOCIN; PEPTIDES AND PROTEINS; PLACEBO; PROTEIN ARC; PROTEIN HOMER; PROTEIN MAP1B; PROTEIN STEP; RG 7090; RILUZOLE; RO 4917523; SERTRALINE; STX 107; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID; BASIMGLURANT; DEXAMPHETAMINE; MEMANTINE; METABOTROPIC RECEPTOR; METHYLPHENIDATE; SEROTONIN UPTAKE INHIBITOR;

DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FMR1 GENE; FRAGILE X SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; KNOCKOUT MOUSE; LONG TERM DEPRESSION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX DIFFERENCE; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT; BEHAVIOR ASSESSMENT; CLINICAL EFFECTIVENESS; EXCITATORY POSTSYNAPTIC POTENTIAL; GENETIC ASSOCIATION; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TIME TO TREATMENT;

ANIMALS; BIOMEDICAL RESEARCH; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MICE; MICE, KNOCKOUT; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, GABA;

EID: 84899730390     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.73r08774     Document Type: Review

References (155)

1. Hagerman PJ. The fragile X prevalence paradox. I Med Genet. 2008;45(8):498-499.
2. Coffee B, Keith K, Albizua I, et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am JHum Genet. 2009;85(4):503-514.
3. Fernandez Carvajal I, Walichiewicz P, Xiaosen X, et al. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. I Mol Diagn. 2009;1-1 (4):324-329.
4. Gross C, Berry Kravis EM, Bassell GJ. Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology. 20-12;37(1 ): 178-195.
5. Hampson DR, Adusei DC, Pacey LK. The neurochemical basis for the treatment of autism spectrum disorders and fragile X syndrome. Biochem Pharmacol. 2011;81(9):1078-1086.
6. McLennan Y, Polussa J, Tassone F, et al. Fragile X syndrome. Curr Genomics. 2011;12(3):216-224.
7. Hagerman R, Au J, Hagerman P. FMR1 premutation and full mutation molecular mechanisms related to autism. J Neurodev Disord. 2011;3(3):211-224.
8. Cordeiro L, Ballinger E, Hagerman R, et al. Clinical assessment of DSM IV anxiety disorders in fragile X syndrome: Prevalence and characterization. JNeurodevDisord. 2011;3(1):57-67.
9. Fisch GS, Simensen RJ, Schroer RJ. Longitudinal changes in cognitive and adaptive behavior scores in children and adolescents with the fragile X mutation or autism. I Autism Dcv Disord. 2002;32(2):107-114.
10. Hagerman RJ, Jackson C, Amiri K, et al. Girls with fragile X syndrome: Physical and neurocognitive status and outcome. Pediatrics. 1992;89(3):395-400.
11. Bailey DB Jr, Raspa M, Olmsted M, et al. Co occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am I Med GenetA. 2008;146A(16):2060-2069.
12. Bailey DB Jr, Raspa M, Bishop E, et al. No change in the age of diagnosis for fragile X syndrome: Findings from a national parent survey. Pediatrics. 2009;124(2):527-533.
13. Kemper AR, Bailey DB Jr. Pediatricians? knowledge of and attitudes toward fragile X syndrome screening. Acad Pediatr. 2009;9(2) :114-117.
14. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR 1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905-914.
15. Kirchgessner CU, Warren ST, Willard HE X inactivation of the FMR1 fragile X mental retardation gene. JMed Genet. 1995;32(12):925-929.
16. McConkie Rosell A, Abrams L, Finucane B, et al. Recommendations from multi disciplinary focus groups on cascade testing and genetic counseling for fragile X associated disorders. I Genet Couns. 2007;16(5):593-606.
17. Godler DE, Tassone F, Loesch DZ, et al. Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet. 2010;19(8):1618-1632.
18. Kumari D, Usdin K. The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome. Hum Mol Genet. 2010;19(23):4634-4642.
19. Pietrobono R, Tabolacci E, Zalfa F, et al. Molecular dissection of the events leading to inactivation of the FMR1 gene. Hum Mol Genet. 2005;14(2):267-277.
20. Chonchaiya W, Au J, Schneider A, et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co morbid autism spectrum disorder. Hum Genet. 2012;131(4):581-589.
21. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention deficit/hyperactivity disorder in boys with the fragile X premutation. I Dcv Behav Pediatr. 2006;27(suppl 2):5137 S 144.
22. Garcia Arocena D, Hagerman PJ. Advances in understanding the molecular basis of FXTAS. Hum Mol Genet. 2010;19(R1):R83 R89.
23. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. I Clin Psychiatry. 2011;72(2):175-182.
24. Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune mediated disorders among women carriers of fragile X premutation alleles. Am I Med Genet A. 2012;158A(10):2473-2481.
25. Hamlin AA, Sukharev D, Campos L, et al. Hypertension in FMR1 premutation males with and without fragile X associated tremor/ataxia syndrome (FXTAS). Am JMed GenetA. 2012;158A(6):1304-1309.
26. Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 201-1;29(4):299-307.
27. Allen EG, He W, Yadav Shah M, et al. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet. 2004;114(5):439-447.
28. Tassone F, Hagerman RJ, Taylor AK, et al. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile X syndrome. AmJHum Genet. 2000;66(1):6
29. Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X associated tremor/ ataxia syndrome. Lancet Neurol. 20-13;12(8):786-798.
30. Bodega B, Bione S, Dalpra L, et al. Influence of intermediate and uninterrupted FMR1 CGG expansions in premature ovarian failure manifestation. Hum Reprod. 2006;2t(4):952-957.
31. Hall D, Tassone F, Klepitskaya 0, et al. Fragile X associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord. 2012;27(2):296-300.
32. Fernandez Carvajal I, Lopez Posadas B, Pan R, et al. Expansion of an FMR1 grey zone allele to a full mutation in two generations. I Mol Diagn. 2009;11(4):306-310.
33. Devys D, Lutz Y, Rouyer N, et al. The FMR 1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet. 1993;4(4):335-340.
34. Abitbol M, Menini C, Delezoide AL, et al. Nucleus basalis magnocellularis and hippocampus are the major sites of FMR 1 expression in the human fetal brain. Nat Genet. 1993;4(2):147-153.
35. Hinds HL, Ashley CT, Sutcliffe JS, et al. Tissue specific expression of FMR 1 provides evidence for a functional role in fragile X syndrome. Nat Genet. 1993;3(1):36
36. Dyer Friedman J, Glaser B, Hessl D, et al. Genetic and environmental influences on the cognitive outcomes of children with fragile X syndrome. I Am Acad Child Adolesc Psychiatry. 2002;41(3):237-244.
37. Loesch DZ, Huggins PM, Hagerman RJ. Phenotypic variation and FM1{P levels in fragile X. Ment Retard Dcv Disabil Res Rev. 2004;10( 1) :31
38. Tassone F, Hagerman RJ, Ikl? DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am I Med Genet. 1999;84(3):250-261.
39. Levenga J, de Vrij FM, Oostra BA, et al. Potential therapeutic interventions for fragile X syndrome. Trends Mol Med. 2010;16(1-1):516-527.
40. Pfeiffer BE, Huber KM. The state of synapses in fragile X syndrome. Neuroscientist. 2009;15(5):549-567.
41. Gallagher A, Hallahan B. Fragile X associated disorders: A clinical overview. JNeurol. 2012;259(3):401-413.
42. Penagarikano 0, Muile JG, Warren ST. The pathophysiology of fragile x syndrome. Annu Rev Genomics Hum Genet. 2007;8(1):109-129.
43. Willemsen R, Levenga J, Oostra BA. CGG repeat in the FMR1 gene: Size matters. Clin Genet. 2011;80(3):214-225.
44. Ceman S, O?Donnell WT, Reed M, et al. Phosphorylation influences the translation state of FMRP associated polyribosomes. Hum Mol Genet. 2003;12(24):3295-3305.
45. Darnell JC, Van Driesche SJ, Zhang C, et al. FMRP stalls ribosomal translocation on milNAs linked to synaptic function and autism. Cell. 2011;146(2):247-261.
46. Brown V, Jin P, Ceman S, et al. Microarray identification of FMRP associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell. 2001;107(4):477-487.
47. Muddashetty RS, Keli? S, Gross C, et al. Dysregulated metabotropic glutamate receptor dependent translation of AMPA receptor and postsynaptic density 95 mRNAs at synapses in a mouse model of fragile X syndrome. I Neurosci. 2007;27(20) :5338-5348.
48. Zalfa F, Giorgi M, Primerano B, et al. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell. 2003;112(3):317-327.
49. Pfeiffer BE, Zang T, Wilkerson JR, et al. Fragile X mental retardation protein is required for synapse elimination by the activity dependent transcription factor MEF2. Neuron. 2010;66(2):191-197.
50. Goebel Goody SM, Wilson Wallis ED, Royston S, et al. Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model. Genes Brain Behav. 2012;11(5):586-600.
51. Schfltt J, Falley K, Richter D, et al. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. I Biol Chem. 2009;284(38):25479-25487.
52. Paluszkiewicz SM, Martin BS, Huntsman MM. Fragile X syndrome: The GABAergic system and circuit dysfunction. Dcv Neurosci. 2011;33(5):349-364.
53. Comery TA, Harris JB, Willems PJ, et al. Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits. Proc NatI Acad Sci USA. 1997;94(10):5401-5404.
54. Larson J, Kim D, Patel RC, et al. Olfactory discrimination learning in mice lacking the fragile X mental retardation protein. Neurobiol Learn Mem. 2008;90(1):90-102.
55. Koekkoek SK, Yamaguchi K, Milojkovic BA, et al. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron. 2005;47(3):339-352.
56. Brennan FX, Albeck DS, Paylor R. Fmrl knockout mice are impaired in a leverpress escape/avoidance task. Genes Brain Behav. 2006;5(6):467-471.
57. Mines MA, Yuskaitis CJ, King MK, et al. GSK3 influences social preference and anxiety related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE. 2010;5(3):e9706.
58. Spencer CM, Graham DF, Yuva Paylor LA, et al. Social behavior in Fmrl knockout mice carrying a human FMR1 transgene. Behav Neurosci. 2008;122(3):710-715.
59. Gibson JR, Bartley AF, Hays SA, et al. Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. JNeurophysiol. 2008;100(5):2615-2626.
60. Qin M, Kang J, Burlin TV, et al. Postadolescent changes in regional cerebral protein synthesis: An in vivo study in the FMR1 null mouse. I Neurosci. 2005;25(20):5087-5095.
61. Curia G, Gualtieri F, Bartolomeo R, et al. Resilience to audiogenic seizures is associated with p ERK1/2 dephosphorylation in the subiculum of Fmrl knockout mice. Front Cell Neurosci. 2013;7:46.
62. Chonchaiya W, Schneider A, Hagerman RJ. Fragile X: A family of disorders. AdvPediatr. 2009;56(1):165-186.
63. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370-377.
64. Gantois I, Vandesompele J, Speleman F, et al. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. NeurobiolDis. 2006;21(2):346-357.
65. Gladding CM, Fitzjohn SM, Molnar E. Metabotropic glutamate receptor mediated long term depression: Molecular mechanisms. Pharmacol Rev. 2009;61(4):395-412.
66. Collingridge GL, Peineau S, Howland JG, et al. Long term depression in the CNS. Nat Rev Neurosci. 2010;11(7):459-473.
67. Moult PR, Gladding CM, Sanderson TM, et al. Tyrosine phosphatases regulate AMPA receptor trafficking during metabotropic glutamate receptor mediated long term depression. I Neurosci. 2006;26(9):2544-2554.
68. Xiao MY, Zhou Q, Nicoll RA. Metabotropic glutamate receptor activation causes a rapid redistribution of AMPA receptors. Neuropharmacology. 2001;41(6):664-671.
69. Waung MW, Pfeiffer BE, Nosyreva ED, et al. Rapid translation of Arc/Arg3.1 selectively mediates mGluR dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron. 2008;59(1):84
70. Waung MW, Huber KM. Protein translation in synaptic plasticity: MGluR LTD, Fragile X. Curr Opin Neurobiol. 2009;19(3):319-326.
71. Davidkova G, Carroll RC. Characterization of the role of microtubule associated protein lB in metabotropic glutamate receptor mediated endocytosis of AMPA receptors in hippocampus. JNeurosci. 2007;27(48):13273-13278.
72. Hou L, Antion MD, Hu D, et al. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR dependent long term depression. Neuron. 2006;51(4):441-454.
73. Park S, Park JM, Kim S, et al. Elongation factor 2 and fragile X mental retardation protein control the dynamic translation of Arc/Arg3.1 essential for mGluR LTD. Neuron. 2008;59(1):70
74. Zhang Y, Venkitaramani DV, Gladding CM, et al. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. I Neurosci. 2008;28(42): 10561-10566.
75. Mao L, Yang L, Tang Q, et al. The scaffold protein Homerlb/c links metabotropic glutamate receptor 5 to extracellular signal regulated protein kinase cascades in neurons. I Neurosci. 2005;25(10):2741-2752.
76. Rong R, Ahn JY, Huang H, et al. P13 kinase enhancer Homer complex couples mG1uRI to P13 kinase, preventing neuronal apoptosis. Nat Neurosci. 2003;6(11):1153-1161.
77. Lyford GL, Yamagata K, Kaufmann WE, et al. Arc, a growth factor and activity regulated gene, encodes a novel cytoskeleton associated protein that is enriched in neuronal dendrites. Neuron. 1995;14(2):433-445.
78. Steward 0, Wallace CS, Lyford GL, et al. Synaptic activation causes the mRNA for the lEG Arc to localize selectively near activated postsynaptic sites on dendrites. Neuron. 1998;21(4):741-751.
79. Chowdhury S, Shepherd JD, Okuno H, et al. Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking. Neuron. 2006;52(3):445-459.
80. Seog DH. Glutamate receptor interacting protein 1 protein binds to the microtubule associated protein. Biosci Biotechnol Biochem. 2004;68(8):1808-1810.
81. Halpain S, Dehmelt L. The MAP1 family of microtubule associated proteins. Genome Biol. 2006;7(6):224.
82. Maurin JC, Couble ML, Staquet MJ, et al. Microtubule associated protein ib, a neuronal marker involved in odontoblast differentiation. I Endod. 2009;35(7):992-996.
83. Ronesi JA, Huber KM. Homer interactions are necessary for metabotropic glutamate receptor induced long term depression and translational activation. I Neurosci. 2008;28(2):543-547.
84. Napoli I, Mercaldo ?4 Boyl PP, et al. The fragile X syndrome protein represses activity dependent translatinn thrnugh CYFIP1, a new 4E BP. Cell. 2008;t34(6):t042-1054.
85. Wang H, Kim 55, Zhuo M. Roles nf fragile X mental retardation protein in dopaminergic stimulation induced synapse associated protein synthesis and subsequent alpha amino 3 hydroxyl 5 methyl 4 isoxazole 4 propionate (AMPA) receptor internalization. JBiol Chem. 2010;285(28):21888-21901.
86. Zalfa F, Eleuteri B, Dickson KS, et al. A new function for the fragile X mental retardation protein in regulation of PSD 95 mRNA stability. Nat Neurosci. 2007;10(5):578-587.
87. Muddashetty RS, Nalavadi VC, Gross C, et al. Reversible inhibition of PSD 95 mRNA translation by miR 125a, FMRP phosphorylation, and mGluR signaling. Mol Cell. 2011;42(5):673-688.
88. Narayanan U, Nalavadi V, Nakamoto M, et al. FMRP phosphorylation reveals an immediate early signaling pathway triggered by group I mGluR and mediated by PP2A. JNeurosci. 2007;27(52):14349-14357.
89. Dolen G, Osterweil E, Rao BS, et al. Correction of fragile X syndrome in mice. Neuron. 2007;56(6):955-962.
90. Krueger DD, Bear ME Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med. 2011;62(1):411-429.
91. Gasparini F, Lingenhohl K, Stoehr N, et al. 2 Methyl 6 (phenylethynyl) pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology. 1999;38(10): 1493-1503.
92. Yan QJ, Rammal M, Tranfaglia M, et al. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology. 2005;49(7) :1053-1066.
93. de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmrl KO mice. NeurobiolDis. 2008;31(1):127-132.
94. Aschrafi A, Cunningham BA, Edelman GM, et al. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc Natl Acad Sci USA. 2005;102(6):2180-2185.
95. Osterweil EK, Krueger DD, Reinhold K, et al. Hypersensitivity to mGluR5 and E1{K1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. I Neurosci. 2010;30(46):15616-15627.
96. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron. 2012;74(1):49
97. Heulens I, D?Hulst C, Braat S, et al. Involvement and therapeutic potential of the GABAergic system in the fragile X syndrome. ScientJicWorldJournal. 2010;10:2198-2206.
98. D?Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res. 2006;1121(1):238-245.
99. Adusei DC, Pacey LK, Chen D, et al. Early developmental alterations in GABAergic protein expression in fragile X knockout mice. Neuropharmacology. 2010;59(3):167-171.
100. El Idrissi A, Ding XH, Scalia J, et al. Decreased GABA(A) receptor expression in the seizure prone fragile X mouse. Neurosci Lett. 2005;377(3):141-146.
101. Olmos Serrano JL, Paluszkiewicz SM, Martin BS, et al. Defective GABAergic neurotransmission and pharmacological rescue of neuronal hyperexcitability in the amygdala in a mouse model of fragile X syndrome. JNeurosci. 2010;30(29):9929-9938.
102. Heulens I, D?Hulst C, Van Dam D, et al. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res. 2012;229(1):244-249.
103. Ehrlich I, Humeau Y, Grenier F, et al. Amygdala inhibitory circuits and the control of fear memory. Neuron. 2009;62(6):757-771.
104. Farrant M, Nusser Z. Variations on an inhibitory theme: Phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005;6(3):215-229.
105. Semyanov A, Walker MC, Kullmann DM, et al. Tonically active GABA A receptors: Modulating gain and maintaining the tone. Trends Neurosci. 2004;27(5):262-269.
106. Curia G, Papouin T, Seguela P, et al. Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome. Cereb Cortex. 2009;19(7):1515-1520.
107. Vigot R, Barbieri S, Br?uner Osborne H, et al. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron. 2006;50(4):589-601.
108. Pacey LK, Doss L, Cifelli C, et al. Genetic deletion of regulator of G protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol Cell Neurosci. 2011;46(3):563-572.
109. Fatemi SH, Folsom TD, Reutiman TJ, et al. Expression of GABA(B) receptors is altered in brains of subjects with autism. Cerebellum. 2009;8(1):64-69.
110. Pacey LK, Heximer S Hampson DR. Increased GABA(B) receptor mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol. 2009;76(1):18-24.
111. Zupan B, Toth M. Inactivation of the maternal fragile X gene results in sensitization of GABA B receptor function in the offspring. I Pharmacol Exp Ther. 2008;327(3):820-826.
112. Iossifov I, Ronemus M, Levy D, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74(2):285-299.
113. Luo Y, Shan G, Guo W, et al. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010;6(4):e1000898.
114. Suvrathan A, Hoeffer CA, Wong H, et al. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc NatI Acad Sci US A. 2010;107(25):1-1591-11596.
115. Wilson BM, Cox CL. Absence of metabotropic glutamate receptor mediated plasticity in the neocortex of fragile X mice. Proc NatI Acad Sci US A. 2007;104(7) :2454-2459.
116. Cruz Martin A, Crespo M, Portera Cailliau C. Delayed stabilization of dendritic spines in fragile X mice. JNeurosci. 2010;30(23):7793-7803.
117. Centonze D, Rossi S, Mercaldo V, et al. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol Psychiatry. 2008;63(10):963-973.
118. Hoeft F, Hernandez A, Parthasarathy S, et al. Fronto striatal dysfunction and potential compensatory mechanisms in male adolescents with fragile X syndrome. Hum Brain Mapp. 2007;28(6):543-554.
119. Dahlhaus R, El Husseini A. Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome. Behav Brain Res. 2010;208(1):96-105.
120. Dziembowska M, Pretto DI, Janusz A, et al. High MMP 9 activity levels in fragile X syndrome are lowered by minocycline. Am I Med Genet A. 2013;161A(8):1897-1903.
121. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. JMed Genet. 2009;46(2):94-102.
122. Rotschafer SE, Trujillo MS, Dansie LE, et al. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Res. 2012;1439:7-14.
123. Romero Zerbo Y, Decara J, el Bekay R, et al. Protective effects of melatonin against oxidative stress in Fmrl knockout mice: A therapeutic research model for the fragile X syndrome. I Pineal Res. 2009;46(2):224-234.
124. de Diego Otero Y, Romero Zerbo Y, el Bekay R, et al. Alpha tocopherol protects against oxidative stress in the fragile X knockout mouse: An experimental therapeutic approach for the Fmrl deficiency. Neuropsychopharmacology. 2009;34(4): 1011-1026.
125. Hagerman R, Lauterborn J, Au J, et al. Fragile X syndrome and targeted treatment trials. Results Probl Cell Dffer. 20-12;54:297-335.
126. Wei H, Dobkin C, Sheikh AM, et al. The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome. PLoS ONE. 2012;7(5):e36981.
127. Hagerman RJ, Berry Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123(1):378-390.
128. Rueda JR, Ballesteros J, Tejada MI. Systematic review of pharmacological treatments in fragile X syndrome. BMC Neurol. 2009;9(1):53.
129. Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am I Med Genet. 1988;30(1-2):377-392.
130. Interim guidance about avian influenza A for US citizens living abroad. Centers for Disease Control and Prevention Web site. http://wwwnc.cdc.gov/ travel. Updated November 18, 2005. Accessed August 10, 2007.
131. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQO56. Sci Transl Med. 2011;3(64):64ra1.
132. Berry Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. I Med Genet. 2009;46(4): 266-271.
133. Berry Kravis EM, Hessl D, Rathmell B, et al. Effects of 5TX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4(152):152ra127.
134. Erickson CA, Mullett JE, McDougle CJ. Brief report: Acamprosate in fragile X syndrome. JAutism Dcv Disord. 2010;40(11):1412-1416.
135. Wink L, Erickson CA, Early M, et al. A pilot naturalistic trial of acamprosate in idiopathic and fragile X associated autism spectrum disorders. International Meeting for Autism Research; May 13,2011; Manchester, United Kingdom.
136. Utari A, Chonchaiya ?N, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dcv Disabil. 2010;1-15(5):433-443.
137. Paribeflo C, Tao L, Folino A, et al. Open label add on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 2010;10(1 ):91.
138. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double blind, placebo controlled trial of minocycline in children and adolescents with fragile x syndrome. JDev Behav Pediatr. 2013;34(3):147-155.
139. Berry Kravis E, Sumis A, Hervey C, et al. Open label treatment trial of lithium to target the underlying defect in fragile X syndrome. I Dcv Behav Pediatr. 2008;29(4):293-302.
140. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. I Clin Sleep Med. 2009;5(2):145-150.
141. Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS study. Am I Med GenetA. 2009;149A(3):403-407.
142. Winarni TI, Chonchaiya W, Adams E, et al. Sertraline may improve language developmental trajectory in young children with fragile X syndrome: A retrospective chart review. Autism Res Treat. 20-12;20-12: 1043-17.
143. Erickson CA, Muflett JE, McDougle CJ. Open label memantine in fragile X syndrome. JAutism Dcv Disord. 2009;39(12):1629-1635.
144. Erickson CA, Weng N, Weiler IJ, et al. Open label riluzole in fragile X syndrome. Brain Res. 2011;1380:264-270.
145. Berry Kravis E, Krause SE, Block SS, et al. Effect ofCXSl6, an AMPA modulating compound, on cognition and behavior in fragile X syndrome: A controlled trial. I Child Adolesc Psychopharmacol. 2006;16(5) :525-540.
146. Henderson C, Wijetunge L, Kinoshita MN, et al. Reversal of disease related pathologies in the fragile X mouse model by selective activation of GABA B receptors with arbaclofen. Sci Transl Med. 2012;4(152): 152ra128.
147. Kerrigan JF, Shields WD, Nelson TY, et al. Ganaxolone for treating intractable infantile spasms: A multicenter, open label, add on trial. Epilepsy Res. 2000;42(2-3):133-139.
148. Laxer K, Blum D, Abou Khalil BW, et al; Ganaxolone Presurgical Study Group. Assessment of ganaxolone?s anticonvulsant activity using a randomized, double blind, presurgical trial design. Epilepsia. 2000;41(9):1187-1194.
149. Berry Kravis E, Sumis A, Hervey C, et al. Open label treatment trial of lithium to target the underlying defect in fragile X syndrome. The 11th International Fragile X Conference; July 23-27, 2008; St Louis, Missouri.
150. Hall SS, Lightbody AA, McCarthy BE, et al. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012;37(4):509-518.
151. Dawson G, Rogers S, Munson J, et al. Randomized, controlled trial of an intervention for toddlers with autism: The Early Start Denver Model. Pediatrics. 2010;125(1):e17 e23.
152. Restivo L, Ferrari F, Passino E, et al. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc NatI Acad Sci USA. 2005;102(32):11557-11562.
153. Winarni TI, Schneider A, Borodyanskara M, et al. Early intervention combined with targeted treatment promotes cognitive and behavioral improvements in young children with fragile X syndrome. Case Rep Genet. 2012;20-12:2808-13
154. Schneider A, Leigh MJ, Adams Ret al. Electrocortical changes associated with minocycline treatment in fragile X syndrome. JPsychopharmacol. 2013;27(10):956-963.
155. Abrams L, Cronister A, Brown WT, et al. Newborn, carrier, and early childhood screening recommendations for fragile X. Pediatrics. 2012;130(6):1126-1135.